Login to Your Account



Other News To Note


Tuesday, April 16, 2013

• BioAlliance Pharma SA, of Paris, said it received marketing authorization from the FDA for Sitavig (acyclovir Lauriad) in the treatment of recurring herpes labialis, marking the successful conclusion to the assessment procedure carried out by the American authorities. The drug is marketed in Europe as Sitavir.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription